Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.

Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta HJ, McFadden G, Kaye FJ, Zajac-Kaye M.

J Clin Invest. 2019 Apr 29;130:2279-2292. doi: 10.1172/JCI121323. eCollection 2019 Apr 29.

2.

Adaptive Transcriptional Responses by CRTC Coactivators in Cancer.

Tasoulas J, Rodon L, Kaye FJ, Montminy M, Amelio AL.

Trends Cancer. 2019 Feb;5(2):111-127. doi: 10.1016/j.trecan.2018.12.002. Epub 2019 Jan 29. Review.

PMID:
30755304
3.

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.

Gopalan PK, Villegas AG, Cao C, Pinder-Schenck M, Chiappori A, Hou W, Zajac-Kaye M, Ivey AM, Kaye FJ.

Oncotarget. 2018 Dec 21;9(100):37352-37366. doi: 10.18632/oncotarget.26424. eCollection 2018 Dec 21.

4.

Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.

Mayfield JD, Mercado CE, Kaye FJ, Mendenhall WM.

Head Neck. 2019 Apr;41(4):E55-E58. doi: 10.1002/hed.25528. Epub 2019 Jan 5.

PMID:
30614125
5.

Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.

Yang R, Li SW, Chen Z, Zhou X, Ni W, Fu DA, Lu J, Kaye FJ, Wu L.

J Natl Cancer Inst. 2018 Nov 13. doi: 10.1093/jnci/djy166. [Epub ahead of print]

PMID:
30423141
6.

Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose.

Zhu S, Lightsey JL, Hoppe BS, Okunieff P, Gopalan PK, Kaye FJ, Morris CG, Yeung AR.

Cancer Invest. 2018;36(5):289-295. doi: 10.1080/07357907.2018.1479415. Epub 2018 Jul 24.

PMID:
30040495
7.

CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells.

Chen Z, Lin S, Li JL, Ni W, Guo R, Lu J, Kaye FJ, Wu L.

Oncogene. 2018 Apr;37(14):1885-1895. doi: 10.1038/s41388-017-0104-0. Epub 2018 Jan 22.

8.

Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.

Sundaresan V, Lin VT, Liang F, Kaye FJ, Kawabata-Iwakawa R, Shiraishi K, Kohno T, Yokota J, Zhou L.

Cancer Genet. 2017 Oct;216-217:20-28. doi: 10.1016/j.cancergen.2017.05.003. Epub 2017 Jun 7.

9.

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.

Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Ares LP.

Clin Lung Cancer. 2017 Jan;18(1):68-76.e2. doi: 10.1016/j.cllc.2016.09.002. Epub 2016 Oct 3.

10.

Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.

Chen M, Maeng K, Nawab A, Francois RA, Bray JK, Reinhard MK, Boye SL, Hauswirth WW, Kaye FJ, Aslanidi G, Srivastava A, Zajac-Kaye M.

Hum Gene Ther Methods. 2017 Feb;28(1):49-59. doi: 10.1089/hgtb.2016.089.

11.

Response.

Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW.

J Natl Cancer Inst. 2016 Sep 26;109(1). pii: djw191. Print 2017 Jan. No abstract available.

PMID:
27671685
12.

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.

Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L.

J Clin Invest. 2016 Jun 1;126(6):2267-79. doi: 10.1172/JCI85250. Epub 2016 May 3.

13.

A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD.

J Thorac Oncol. 2016 Jun;11(6):838-49. doi: 10.1016/j.jtho.2016.02.009. Epub 2016 Feb 23.

14.

Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy.

Kennedy WR, Werning JW, Kaye FJ, Mendenhall WM.

Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3293-7. doi: 10.1007/s00405-016-3899-3. Epub 2016 Jan 21.

PMID:
26796877
15.

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.

François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.

J Natl Cancer Inst. 2015 May 12;107(8). pii: djv123. doi: 10.1093/jnci/djv123. Print 2015 Aug.

16.

Re: a cancer theory kerfuffle can lead to new lines of research.

Kaye FJ.

J Natl Cancer Inst. 2015 Mar 11;107(5). pii: djv060. doi: 10.1093/jnci/djv060. No abstract available.

PMID:
25766401
17.

A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.

Gao R, Cao C, Zhang M, Lopez MC, Yan Y, Chen Z, Mitani Y, Zhang L, Zajac-Kaye M, Liu B, Wu L, Renne R, Baker HV, El-Naggar A, Kaye FJ.

Oncotarget. 2014 Dec 30;5(24):12528-42.

18.

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW.

J Natl Cancer Inst. 2014 Dec 3;107(1):378. doi: 10.1093/jnci/dju378. Print 2015 Jan. No abstract available.

PMID:
25475564
19.

Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.

Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ.

J Natl Cancer Inst. 2014 Dec 1;107(1):358. doi: 10.1093/jnci/dju358. Print 2015 Jan.

20.

CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.

Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, Southern MR, Young BM, Wu L, Zajac-Kaye M, Kaye FJ, Cleveland JL, Conkright MD.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3260-8. doi: 10.1073/pnas.1319176111. Epub 2014 Jul 28.

21.

Recurrent dermatophytosis (Majocchi granuloma) associated with chemotherapy-induced neutropenia.

Lourdes LS, Mitchell CL, Glavin FL, Schain DC, Kaye FJ.

J Clin Oncol. 2014 Sep 20;32(27):e92-4. No abstract available.

PMID:
24470005
22.

Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.

Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.

Int J Cancer. 2014 Jul 1;135(1):128-37. doi: 10.1002/ijc.28675. Epub 2014 Jan 6.

23.

Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma.

Warner KA, Adams A, Bernardi L, Nor C, Finkel KA, Zhang Z, McLean SA, Helman J, Wolf GT, Divi V, Queimado L, Kaye FJ, Castilho RM, Nör JE.

Oral Oncol. 2013 Nov;49(11):1059-66. doi: 10.1016/j.oraloncology.2013.08.004. Epub 2013 Sep 12.

24.

Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.

Chen Z, Chen J, Gu Y, Hu C, Li JL, Lin S, Shen H, Cao C, Gao R, Li J, Ha PK, Kaye FJ, Griffin JD, Wu L.

Oncogene. 2014 Jul 17;33(29):3869-77. doi: 10.1038/onc.2013.348. Epub 2013 Aug 26.

PMID:
23975434
25.

Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Klorin G, Rozenblum E, Glebov O, Walker RL, Park Y, Meltzer PS, Kirsch IR, Kaye FJ, Roschke AV.

Cancer Genet. 2013 May;206(5):191-205. doi: 10.1016/j.cancergen.2013.04.006. Epub 2013 Jul 5.

26.

The 3rd Salivary Gland Tumor Workshop meeting report.

El-Naggar AK, Kaye FJ, Stenman G.

Head Neck. 2013 Aug;35(8):1057-60. doi: 10.1002/hed.23374. No abstract available.

PMID:
23677839
27.

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M.

Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27.

28.

Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion.

Gu Y, Lin S, Li JL, Nakagawa H, Chen Z, Jin B, Tian L, Ucar DA, Shen H, Lu J, Hochwald SN, Kaye FJ, Wu L.

Oncogene. 2012 Jan 26;31(4):469-79. doi: 10.1038/onc.2011.247. Epub 2011 Jun 27.

PMID:
21706049
29.

Erlotinib or gefitinib for non-small-cell lung cancer.

Kaye FJ, Jantz MA, Dallas J.

N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. No abstract available.

PMID:
21675909
30.

Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.

Dallas JL, Jantz MA, Lightsey JL, Sonntag C, Kaye FJ.

J Thorac Oncol. 2011 Jun;6(6):1142-3. doi: 10.1097/JTO.0b013e318217b684. No abstract available.

31.

CRTC1 expression during normal and abnormal salivary gland development supports a precursor cell origin for mucoepidermoid cancer.

Jaskoll T, Htet K, Abichaker G, Kaye FJ, Melnick M.

Gene Expr Patterns. 2011 Jan-Feb;11(1-2):57-63. doi: 10.1016/j.gep.2010.09.003. Epub 2010 Sep 15.

32.

Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.

Chen M, Voeller D, Marquez VE, Kaye FJ, Steeg PS, Giaccone G, Zajac-Kaye M.

Int J Oncol. 2010 Oct;37(4):963-71.

33.

The landscape of somatic copy-number alteration across human cancers.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.

Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.

34.

Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer.

Komiya T, Coxon A, Park Y, Chen WD, Zajac-Kaye M, Meltzer P, Karpova T, Kaye FJ.

Oncogene. 2010 Mar 18;29(11):1672-80. doi: 10.1038/onc.2009.453. Epub 2009 Dec 14.

PMID:
20010869
35.

Meeting report--the NIDCR 2(nd) Salivary Gland Tumor Meeting, November 2008.

El-Naggar AK, Kaye FJ, Shirazi Y, Gutkind JS, Forastiere AA.

Head Neck. 2009 Dec;31(12):1542-3. doi: 10.1002/hed.21307. No abstract available.

PMID:
19890918
36.

Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions.

Anzick SL, Chen WD, Park Y, Meltzer P, Bell D, El-Naggar AK, Kaye FJ.

Genes Chromosomes Cancer. 2010 Jan;49(1):59-69. doi: 10.1002/gcc.20719.

37.

Mutation-associated fusion cancer genes in solid tumors.

Kaye FJ.

Mol Cancer Ther. 2009 Jun;8(6):1399-408. doi: 10.1158/1535-7163.MCT-09-0135. Epub 2009 Jun 9. Review.

38.

Defining a candidate lung cancer gene.

Kaye FJ.

J Natl Cancer Inst. 2008 Nov 19;100(22):1564-5. doi: 10.1093/jnci/djn381. Epub 2008 Nov 11. No abstract available.

39.

Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Park Y, Kubo A, Komiya T, Coxon A, Beebe K, Neckers L, Meltzer PS, Kaye FJ.

Cell Cycle. 2008 Aug;7(15):2384-91. Epub 2008 May 30.

40.

CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association.

Bell D, Luna MA, Weber RS, Kaye FJ, El-Naggar AK.

Genes Chromosomes Cancer. 2008 Apr;47(4):309-14. doi: 10.1002/gcc.20534.

PMID:
18181164
41.

CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior.

Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK.

Genes Chromosomes Cancer. 2007 Jul;46(7):708-15.

PMID:
17437281
42.

Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.

Chen M, Rahman L, Voeller D, Kastanos E, Yang SX, Feigenbaum L, Allegra C, Kaye FJ, Steeg P, Zajac-Kaye M.

Oncogene. 2007 Jul 19;26(33):4817-24. Epub 2007 Feb 12.

PMID:
17297449
43.
44.

Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.

Komiya T, Park Y, Modi S, Coxon AB, Oh H, Kaye FJ.

Oncogene. 2006 Oct 5;25(45):6128-32. Epub 2006 May 1.

PMID:
16652146
45.

Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes.

Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR, Kaye FJ.

Cancer Res. 2005 Aug 15;65(16):7137-44.

46.
47.

A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands.

Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I.

J Mol Diagn. 2004 Aug;6(3):205-10.

48.

Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas.

Tonon G, Gehlhaus KS, Yonescu R, Kaye FJ, Kirsch IR.

Cancer Genet Cytogenet. 2004 Jul 1;152(1):15-22.

PMID:
15193437
49.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.

Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.

50.

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.

Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M.

Cancer Cell. 2004 Apr;5(4):341-51.

Supplemental Content

Support Center